Hannes Steinkellner has worked during his PhD thesis on advancement of recombinant human erythropoietin (rHuEPO) as a promising therapy for Friedreich’s ataxia. In this work, he has developed a novel tool for the measurement of frataxin protein levels in human and mouse samples. Additionally he has started collaboration with Dr. Franco Laccone on protein replacement therapy for Friedreich’s ataxia. After finishing his PhD-thesis he has joined the scientific group of Dr. Franco Laccone at the Institute of Medical Genetics headed by Prof. Dr. Markus Hengstschläger where he is still working on the development and investigation of TAT (transactivator of transcription)- fusion proteins for neurodevelopmental and neurodegenerative disorders like RETT syndrome and Spinal Muscular Atrophy. Moreover, he is interested in functional characterization of rare genetic diseases.